These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1156118)

  • 1. [On the mode of action of heterologous antileukemic sera. Growth of syngeneically transplanted leukemias in serum-treated sublethally irradiated mice (author's transl)].
    Mileck J
    Arch Geschwulstforsch; 1975; 45(1):40-5. PubMed ID: 1156118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [On the mode of action of heterologous antileukemic sera. Growth of syngeneically transplanted leukemia cells on serum treated neonatally thymectomized mice (author's transl)].
    Milleck J; Petro J; Madri M; Broen B; Eckert R
    Arch Geschwulstforsch; 1975; 45(6):541-4. PubMed ID: 1225257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy.
    Genovesi EV; Pettey CL; Collins JJ
    Cancer Res; 1984 Apr; 44(4):1489-98. PubMed ID: 6608407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [On the effectivity in vitro of heterologous rabbit antisera against mouse leukemia cells (author's transl)].
    Milleck J
    Arch Geschwulstforsch; 1973; 42(4):274-84. PubMed ID: 4138846
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H; Luo Y; Haruta Y; Seon BK
    Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of antileukemia sera prepared by immunization with leukemia cells admixed with normal antigen-blocking sera.
    Smith PJ; Robinson CM; Reif AE
    Cancer Res; 1974 Jan; 34(1):169-75. PubMed ID: 4129197
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum requirements for in vivo modulation of thymus-leukemia antigens on mouse leukemia cells and thymocytes.
    Stackpole CW
    J Natl Cancer Inst; 1979 Jun; 62(6):1529-36. PubMed ID: 312352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive immunotherapy for mouse leukemias with antisera of "directed" specificity: synergism with the action of cyclophosphamide.
    Reif AE; Li RW; Robinson CM
    Cancer Treat Rep; 1977 Nov; 61(8):1499-508. PubMed ID: 922753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of murine leukemia. VIII. Efficacy of passive serum therapy of Friend leukemia virus-induced disease in immunocompromised mice.
    Genovesi EV; Livnat D; Collins JJ
    J Natl Cancer Inst; 1983 Feb; 70(2):311-22. PubMed ID: 6337292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-mediated alteration of antibody specificity in vivo.
    Drake WP; Mardiney MR
    J Immunol; 1975 Mar; 114(3):1052-7. PubMed ID: 46259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo activities of heterologous antisera against mouse leukemias.
    Milleck J; Pasternak G
    Medicina (B Aires); 1976; 36(5):457-62. PubMed ID: 1004205
    [No Abstract]   [Full Text] [Related]  

  • 12. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
    Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
    Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protective effect of antisera against leukaemia in vivo--a reappraisal.
    Hersey P
    Br J Cancer Suppl; 1973 Aug; 1():11-8. PubMed ID: 4807573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice.
    Truitt RL; Bortin MM; Rimm AA
    Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells.
    Kirch ME; Hammerling U
    J Immunol; 1981 Aug; 127(2):805-10. PubMed ID: 6788849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA; Ciavarra R; Riblet R; Forman J
    J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the immune response to transplantation antigens. II. The effects of heterologous antisera on the growth of tumour allografts in mice.
    Zola H
    Clin Exp Immunol; 1974 Mar; 16(3):461-7. PubMed ID: 4468850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-induced killing in vivo of L1210/MTX-R cells quantitated in passively immunized mice with 131I-iododeoxyuridine-labeled cells and whole-body measurement of retained radioactivity.
    Carlson GA; Terres G
    J Immunol; 1976 Sep; 117(3):822-9. PubMed ID: 956654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of blocking by hyperimmune serum of lymphocyte-mediated cytolysis of allogeneic tumor cells.
    Todd RF; Stulting RD; Berke G
    Cancer Res; 1973 Dec; 33(12):3203-8. PubMed ID: 4760536
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of heterologous antireceptor antibodies for specific reversal of acute homologous disease in mice].
    Nesterenko VG; Gruner Sh; Rubakova EI; Babadzhanov AS
    Biull Eksp Biol Med; 1980 Nov; 90(11):588-90. PubMed ID: 7192584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.